BYAM REBECCA (Chief Financial Officer) purchased 4.9% of their position (24.70K shares) of HCW BIOLOGICS INC. on the open market
Open‑market purchase worth $51.0K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/8/2023ACC: 0001209191-23-035581
Officer· Chief Financial Officer
Since Jul 2021
+24.70K
Net shares
Net buyer
$51.0K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
24.70K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+20K
Price / share
$2.03
Trade value
$40.63K
% of position
4.0%
6/7/2023
499.25K→519.25K
Common Stock
Direct
Shares
+4.70K
Price / share
$2.21
Trade value
$10.39K
% of position
0.9%
6/8/2023
519.25K→523.95K
Total
Net shares
+24.70K
Net value
$51.02K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/7/2023 | P · Purchase | +20K | $2.03 | $40.63K | 4.0% | 499.25K | 519.25K |
| Common Stock Direct | 6/8/2023 | P · Purchase | +4.70K | $2.21 | $10.39K | 0.9% | 519.25K | 523.95K |
| Total | +24.70K | $51.02K | ||||||
Derivative Transactions0
No derivative transactions reported